Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International's Total Liabilities history runs 10 years deep, the most recent figure standing at $219.6 million for Q1 2026.

• Quarterly Total Liabilities rose 54.82% year-over-year to $219.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $219.6 million (up 54.82% YoY) and the FY2025 annual result came in at $196.0 million, up 37.93% from the prior year.
• Total Liabilities was $219.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $196.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $219.6 million in Q1 2026 and bottomed at $52.8 million in Q1 2023.
• A 5-year average of $112.2 million and a median of $87.8 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 95.68% — and 2023, when it fell 18.47%.
• Kiniksa Pharmaceuticals International's Total Liabilities stood at $63.5 million in 2022, then soared by 37.72% to $87.5 million in 2023, then surged by 62.45% to $142.1 million in 2024, then surged by 37.93% to $196.0 million in 2025, then gained by 12.02% to $219.6 million in 2026.
• Business Quant data shows KNSA's Total Liabilities at $219.6 million in Q1 2026, $196.0 million in Q4 2025, and $177.0 million in Q3 2025.